New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
06:57 EDTSLXP, BCRX, QCOR, KERX, AUXL, CBST, IRWD, ACRXBiotech weakness a buying opportunity, says Mizuho
Mizuho said the recent weakness in biotech will prove transient and has created buying opportunities in AcelRx (ACRX), Auxilium (AUXL), BioCryst (BCRX), Ironwood (IRWD), Keryx (KERX), Salix (SLXP), Cubist (CBST), and Questcor (QCOR).
News For ACRX;AUXL;BCRX;IRWD;KERX;SLXP;CBST;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
07:03 EDTACRXAcelRx's Zalviso shows positive results for post-operative pain in Phase 3 trial
Subscribe for More Information
June 30, 2015
10:00 EDTBCRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:26 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTBCRXBioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill
As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both 4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.
06:00 EDTBCRXBioCryst upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use